Fig. 4

Exosomal miR-1249-3p directly targets SKOR1 to mediate insulin sensitivity. a The potential targets of miR-1249-3p were predicted by integrating the results of two databases (TargetScan and miRDB). b Western blot analysis of SKOR1 in 3T3-L1 adipocytes and AML12 cells with the indicated treatments. c The wild-type and a mutated type of binding site between miR-1249-3p and SKOR1. d Relative luciferase activity of AML12 cells in the presence of indicated treatments. e Western blot analysis of SKOR1 expression in the VATs and livers of HFD mice after NCD-Exos or HFD-Exos treatment. f–i The effect of sh-SKOR1 on glucose uptake capacity in 3T3-L1 adipocytes (f), glucose production capacity in AML12 cells (g), and expression levels of IL-6, TNF-α, and IL-1β (h, i). j–q Glucose uptake content of 3T3-L1 adipocytes (j) and glucose production content of AML12 cells (n) with the indicated treatments were measured, as well as the expression levels of IL-6, TNF-α, and IL-1β (k–m and o–q). Experiments were performed at least in triplicate, and the results are shown as the mean ± s.d. Student’s t-test was used to analyze the data. (*P < 0.05; **P < 0.01; ***P < 0.001)